Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856352 | 1.00 | GPR119 (0.48) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL856351 | 1.00 | GPR119 (0.48) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL856350 | 1.00 | GPR119 (0.48) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL29895401 | 1.00 | GPR119 (0.48) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL857313 | 1.00 | GPR119 (0.48) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL2353012 | 0.93 | GPR119 (0.47) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL12942705 | 0.91 | GPR119 (0.48) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL26907202 | 0.90 | KMT2A (0.44) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL27228981 | 0.90 | KMT2A (0.44) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL25819624 | 0.89 | MMP13 (0.48) | GPR119MMP13KMT2AMEN1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11613532-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-03-28 | — | — | US | disclosed |
| EP-4126874-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126875-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2023-02-08 | — | — | EP | disclosed |
| US-20220363683-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2022-11-17 | — | — | US | disclosed |
| US-20220098182-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2022-03-31 | — | — | US | disclosed |
| US-9029368-B2 | 3,7-disubstituted octahydro-2H-pyrido[4,3-E][1,3]oxazin-2-one antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-05-12 | — | — | US | disclosed |
| US-20140309218-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| US-8318742-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20060142339-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | US | disclosed |
| EP-1641784-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4 -ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641783-A1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641782-A1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638959-A1 | 5HT -4 -ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005003122-A1 | 5HT4-ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003121-A1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000838-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000837-A1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| EP-1206938-A1 | Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)- piperdine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | GPR119 56/4885MMP13 3328/4885KMT2A 3180/4885 |
| US-20220363683-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | GPR119 56/4885MMP13 3328/4885KMT2A 3180/4885 |
| US-20220098182-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | GPR119 56/4885MMP13 3328/4885KMT2A 3180/4885 |
| US-20060142339-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists | HTR4, HTR2B, HTR2C | GPR119 180/4885MMP13 3320/4885KMT2A 478/4885 |
| US-11613532-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | GPR119 56/4885MMP13 3328/4885KMT2A 3180/4885 |
| US-20140309218-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | OXA1L, TOP1, OGFOD1 | GPR119 4350/4885MMP13 2561/4885KMT2A 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.